Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies

• Published in: Biochemical and biophysical research communications Vol. 538; pp. 192 - 203
• Main Authors: Yuan, Meng, Liu, Hejun, Wu, Nicholas C., Wilson, Ian A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 29.01.2021; Elsevier
• Subjects: Angiotensin-Converting Enzyme 2 - chemistry; Angiotensin-Converting Enzyme 2 - immunology; Antibodies, Neutralizing - immunology; Antibodies, Viral - immunology; Antibody avidity; antibody formation; Binding Sites - immunology; COVID-19 infection; Cross-neutralization; Epitopes; Germline-encoded motifs; Humans; Neutralizing antibodies; pandemic; Protein Binding - immunology; Protein Domains - immunology; RBD natural mutations; Receptor binding domain (RBD); Receptors, Virus - chemistry; Receptors, Virus - immunology; SARS-CoV; SARS-CoV-2; SARS-CoV-2 - immunology; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - immunology; therapeutics; vaccines; viruses; Receptor binding domain (RBD); SARS-CoV-2; Germline-encoded motifs; Cross-neutralization; Antibody avidity; Neutralizing antibodies; SARS-CoV; RBD natural mutations; Epitopes

Immediately from the outset of the COVID-19 pandemic, researchers from diverse biomedical and biological disciplines have united to study the novel pandemic virus, SARS-CoV-2. The antibody response to SARS-CoV-2 has been a major focus of COVID-19 research due to its clinical relevance and importance...